Wikisage, the free encyclopedia of the second generation, is digital heritage

Belzutifan

From Wikisage
Revision as of 23:28, 13 August 2021 by Penarc (talk | contribs) (→‎ATC)
Jump to navigation Jump to search

Belzutifan is a drug being approved for the treatment of renal cell carcinoma associated with von Hippel-Lindau disease.

Belzutifan is an inhibitor of hypoxia-inducible factor 2 alpha (HIF-2α).

Belzutifan is the first drug to be awarded an "innovation passport" by the UK Medicines and Healthcare products Regulatory Agency (MHRA)[1]

ATC

none

belzutifan

Retinal angioma associated with cerebellar angioma and sometimes angioma in other organs[2]

Q27456641 at Wikidata  Interwiki via Wikidata

  1. ↑ https://en.wikipedia.org/wiki/Medicines_and_Healthcare_products_Regulatory_Agency
  2. ↑ Dictionary of Medical eponyms
Retrieved from "https://en.wikisage.org/w/index.php?title=Belzutifan&oldid=10631"